Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Marrone Bio Innovations Announces Zequanox® Distribution Partnership


Posted on: 15 Mar 18

DAVIS, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII) (MBI), a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental and water treatment markets, today announced that it has signed an exclusive distribution agreement with Solenis, a global expert in water treatment and process chemistries, to provide Zequanox® molluscicide treatment programs for enclosed and semi-enclosed water systems in the United States and Canada.

Zequanox molluscicide is a patented, naturally derived aquatic biopesticide that effectively controls all life stages of invasive zebra and quagga (dreissenid) mussels. The molluscicide is manufactured by MBI, at the company’s plant in Michigan and, now supplied exclusively by Solenis in the United States and Canada for industrial water applications.

The cost for treating intake pipes, water filtration equipment, and power plants’ operating costs for zebra mussel damages is estimated at $3.1 billion dollars spent over 10 years.1

“Establishing this partnership with Solenis is a significant milestone in the commercialization of Zequanox. With a direct sales force of water-treatment experts servicing industrial facilities and power generation plants throughout North America, Solenis provides on-site technical service and expertise essential to elevating the profile of Zequanox with major customers that must contend with infrastructure and operational challenges caused by zebra and quagga mussel infestations,” stated Dr. Pam Marrone, Founder and CEO of MBI. 

The active ingredient in Zequanox molluscicide is derived from the dead cells of a specific strain of the naturally occurring bacteria Pseudomonas fluorescens (Pf). Pf is one of the most common bacteria in the world and is present naturally in soil, in water and on plants. Strains of Pf bacteria are regularly used in production of medicines, enzymes and food. Zequanox is not genetically modified. 

“Over the past year, Solenis has worked closely with MBI to evaluate Zequanox and to develop this collaboration. We are excited to have gained a partner with a shared vision to bring effective, innovative and sustainable products to the marketplace.  As a leader in servicing industrial water users, Solenis is pleased to add Zequanox to our broad array of tools and services for our customers,” added David Jellison, Vice President of Solenis’ North America industrial water treatment business.

Extensive studies with Zequanox molluscicide have been conducted on numerous aquatic and terrestrial species, with no indication of any harmful effects when used as instructed.  The molluscicide is food tolerance exempt and deemed safe for use on food crops and in drinking water in the United States.

Unlike other molluscicides, EPA has determined that Zequanox is of negligible risk to humans, with minimal re-entry intervals and personal protection equipment requirements.  Zequanox is non-corrosive to pipes and has no detrimental effects to water quality.

Currently, Zequanox is registered in 37 states for both enclosed system and open water uses where zebra and/or quagga mussels are present, or where the threat of future infestation exists.  The product is also registered in California for enclosed and semi-enclosed systems, with an open-water label amendment pending. 

In Canada, the product is currently approved for use in hydroelectric power facilities.  MBI recently submitted a label amendment dossier to Health Canada that seeks to expand the use of Zequanox for all mussel infested enclosed and semi-enclosed infrastructure, including farm irrigation systems and all industrial facilities using raw water.

1Zegers, R. E. (2008, June 24). (Nevada State Director, Southern Nevada Water Authority). Retrieved March 15, 2016, from http://www.westernais.org/media/economics/snwa.pdf 

Facts About Zequanox

  • Zequanox is composed of dead cells from a naturally occurring strain of the bacteria Pseudomonas fluorescens (Pf). Zebra and quagga mussels perceive Zequanox as a non-threatening food source and consume it readily, along with their normal diet. Once ingested, Zequanox causes their digestive lining to deteriorate, resulting in death.

  • Mussel mortality begins within a couple of days after treatment and continues for several weeks following exposure to the product.

  • Pf as a species have a long history of use in the production of food and pharmaceuticals. It is a species commonly used in the production of fermented food products, such as yogurt.

  • The particular Pf strain used to make Zequanox was isolated from river mud in New York state on a body of water that had notably lower Zebra and quagga mussel populations when compared to surrounding bodies of water.

  • Funding for the initial research to discover Zequanox was supported by the State of New York, the U.S. Department of Energy and the National Science Foundation, with the goal of finding dreissenid mussel controls that were of lower risk to humans, the environment and water quality than products currently in use.

  • Extensive research, both in the laboratory and the field, have demonstrated Zequanox’s efficacy against invasive mussels, little risk to non-target species—including native unionid mussels and important game fish—and no lasting impacts to water quality.

  • In collaboration with MBI, these studies have been completed by a number of institutions including the U.S. Geological Survey, the New York State Museum, the U.S. Bureau of Reclamation, Missouri State University and Southern Illinois University, as well as a variety of independent laboratories, among others.

About Solenis

Solenis is a leading global producer of specialty chemicals for water intensive industries, including the pulp, paper, oil and gas, chemical processing, mining, biorefining, power and municipal markets. The company’s product portfolio includes a broad array of process, functional and water treatment chemistries as well as state-of-the-art monitoring and control systems. These technologies are used by customers to improve operational efficiencies, enhance product quality, protect plant assets and minimize environmental impact. Headquartered in Wilmington, Delaware, the company has 37 manufacturing facilities strategically located around the globe and employs a team of approximately 3,700 professionals in 118 countries across five continents. For additional information about Solenis, please visit www.solenis.com.  

About Marrone Bio Innovations

Bio With Bite.
Marrone Bio Innovations, Inc. (NASDAQ:MBII) strives to lead the movement to a more sustainable world through the discovery, development and promotion of biological products for pest management and plant health. MBI’s effective and environmentally responsible pest management solutions help customers operate more sustainably while uniquely improving plant health and increasing crop yields. MBI’s currently available commercial products are Regalia®, Grandevo®, Venerate®, Majestene®, Haven® StargusTM and AmplitudeTM, ZeltoTM and Zequanox®. MBI also distributes Bio-tam 2.0® for Isagro USA and Jet-Ag® for Jet Harvest in most regions of the U.S.

Marrone Bio Innovations is dedicated to pioneering smart biopesticide solutions that support a better tomorrow for both farmers, turf managers and consumers around the globe. For more information, please visit www.marronebio.com.

Marrone Bio Innovations Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties.  All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date.  Examples of such statements include statements regarding the potential of Zequanox and other MBI products in the US and Canada and other markets, market projections, including the potential benefits of Zequanox and MBI’s plans for expanding additional label uses. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company's control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including consumer, regulatory and other factors affecting demand for the MBI’s products, any difficulty in marketing MBI’s products in its target markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers.  Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC.  MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of current information, future events or otherwise.

Marrone Bio Innovations Contacts:
Pam Marrone, CEO and Founder
Keith Pitts, Chief Sustainability Officer
Telephone: +1 (530) 750-2800
Email: Info@marronebio.com

MBI Investor Relations:
Greg Falesnik
Managing Director
MZ Group – MZ North America
Main: 949-385-6449
MBII@mzgroup.us
www.mzgroup.us

GlobeNewswire
globenewswire.com

Last updated on: 15/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.